Glycolytic enzymes in @entity0 , XXXX and normal breast tissue.

@entity0 @entity5 @entity189 @entity3923 @entity1557 @entity1558 @entity2388
The activities of hexokinase, phosphofructokinase, aldolase, enolase and @entity2388 kinase were studied in @entity0 tissues, in comparison to @entity1558 and normal breast tissues. The enzyme activities in @entity0 were significantly increased compared to normal and benign breast tissues (p less than 0.001). Also the increase in activity in benign disease compared to normal was statistically significant (p less than 0.001). Within the group of benign diseases, @entity1557 could be distinguished from @entity3923 , the former generally showing higher activities compared to the latter (p less than or equal to 0.05). @entity189 subgroups, classified according to their histology, could not be recognized enzymologically. In addition, isozyme composition of @entity2388 kinase and enolase was studied. We did not find a significant shift towards K type @entity2388 kinase expression in benign disease compared to normal breast tissues. Also @entity1557 did not differ from @entity3923 . However, the amount of K type @entity2388 kinase in @entity189 proved to be significantly higher in comparison to benign disease and normal breast tissues (p less than 0.001). Expression of alpha gamma-enolase in normal breast tissue was virtually absent. In benign disease only a minority of specimens did show the hybrid alpha gamma-enolase. Nearly all @entity189 had alpha gamma-enolase expression and in 20% of the @entity189 gamma gamma-enolase could be detected (so-called neuron-specific enolase). By discriminant analysis, the function giving the best discrimination compared to the histological data was based on natural logarithm aldolase and the total of gamma-enolase subunits. Contrary to expectation, the regulator enzymes of glycolysis; i.e., hexokinase, phosphofructokinase and @entity2388 kinase were not included in this discriminant function. The best fit produced a 90% correct classification in both benign and @entity5 . If these findings are confirmed to a larger series, the discrimination is sufficiently strong to form the basis of a clinically useful tool.
